To the 52 week highThe S&P Biotech ETF is 1% from its 52 week high.
AEZS is 100% from its 52 week high.
Gilles acquired the assets at the bottom of the biotech bear market but the market need to know what it is investing in. Will the merger close? What is the go forward plan and priorities for the new company? Add the pediatric data, pediatric approval and a deal on AEZS's diagnostic test plus a clinical trial go decision for a pipeline asset and clinical trial plan plus the successful commissioning of the 10X PGX scale-up and a PGX licensing deal as well as data and deals for wound healing and the avenanthramide pill and how high is high? CZO could also file to commence a fibrosis clinical trial and announce data and a plan for the immune booster. The daisy chain of catalysts could be amazing and all on NASDAQ with potential analyst support!